FDA OKs expanded use of Pfizer's anticoagulant Fragmin

|About: Pfizer Inc. (PFE)|By:, SA News Editor

The FDA has approved Pfizer's (PFE +1.2%) Fragmin (dalteparin sodium) injection to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients at least one month old.

Fragmin, a type of heparin, was first approved in the U.S. in 1994 for adults with certain types of angina or heart attack.

Subscribe for full text news in your inbox